Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

Valentina Angerilli; Juan J. Andrade-Rojas; Matteo Fassan

doi:10.1016/B978-0-443-13376-3.00012-5

Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

Valentina Angerilli
, Juan J. Andrade-Rojas
, Matteo Fassan

Universidad de Cuenca

University of Padua
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Producción científica: Capítulo del libro/informe/acta de congreso › Capítulo › revisión exhaustiva

Resumen

Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.

Idioma original	Inglés
Título de la publicación alojada	Principles of Immunotherapy Breast and Gastrointestinal Cancers
Editores	Michele Ghidini
Editorial	Elsevier, Academic Press
Capítulo	4
Páginas	83-102
ISBN (versión impresa)	978-0-443-13376-3
DOI	https://doi.org/10.1016/B978-0-443-13376-3.00012-5
Estado	Publicada - 2024

Serie de la publicación

Nombre	Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1016/B978-0-443-13376-3.00012-5

Otros archivos y enlaces

https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780443133763000125?via%3Dihub

Citar esto

Angerilli, V., Andrade-Rojas, J. J., & Fassan, M. (2024). Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. En M. Ghidini (Ed.), Principles of Immunotherapy Breast and Gastrointestinal Cancers (pp. 83-102). (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy). Elsevier, Academic Press. https://doi.org/10.1016/B978-0-443-13376-3.00012-5

Angerilli, Valentina ; Andrade-Rojas, Juan J. ; Fassan, Matteo. / Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. Principles of Immunotherapy Breast and Gastrointestinal Cancers. editor / Michele Ghidini. Elsevier, Academic Press, 2024. pp. 83-102 (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy).

@inbook{8a375ebd5c30445a95ca568c4ba13952,

title = "Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers",

abstract = "Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.",

author = "Valentina Angerilli and Andrade-Rojas, \{Juan J.\} and Matteo Fassan",

year = "2024",

doi = "10.1016/B978-0-443-13376-3.00012-5",

language = "Ingl{\'e}s",

isbn = "978-0-443-13376-3",

series = "Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy",

publisher = "Elsevier, Academic Press",

pages = "83--102",

editor = "Michele Ghidini",

booktitle = "Principles of Immunotherapy Breast and Gastrointestinal Cancers",

}

Angerilli, V, Andrade-Rojas, JJ & Fassan, M 2024, Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. En M Ghidini (ed.), Principles of Immunotherapy Breast and Gastrointestinal Cancers. Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy, Elsevier, Academic Press, pp. 83-102. https://doi.org/10.1016/B978-0-443-13376-3.00012-5

Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. / Angerilli, Valentina; Andrade-Rojas, Juan J.; Fassan, Matteo.
Principles of Immunotherapy Breast and Gastrointestinal Cancers. ed. / Michele Ghidini. Elsevier, Academic Press, 2024. p. 83-102 (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy).

Producción científica: Capítulo del libro/informe/acta de congreso › Capítulo › revisión exhaustiva

TY - CHAP

T1 - Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers

AU - Angerilli, Valentina

AU - Andrade-Rojas, Juan J.

AU - Fassan, Matteo

PY - 2024

Y1 - 2024

N2 - Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.

AB - Gastrointestinal (GI) cancers represent a major health burden, especially due to their elevated incidence and poor prognosis. In the past decade, immunotherapy, currently driven by the application of monoclonal antibodies targeting immune checkpoints, has revolutionized the therapeutic landscape of many solid tumors, including GI cancers. Unfortunately, only a subset of patients responds to immune checkpoint inhibitors, and the development of secondary resistance is increasing. In this chapter, we will outline the most relevant biomarkers for gastroesophageal, bowel, anal, and biliopancreatic cancers and gastroenteropancreatic neuroendocrine neoplasms, and we will discuss their prognostic and predictive value and their use in clinical practice.

UR - https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780443133763000125?via%3Dihub

U2 - 10.1016/B978-0-443-13376-3.00012-5

DO - 10.1016/B978-0-443-13376-3.00012-5

M3 - Capítulo

SN - 978-0-443-13376-3

T3 - Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

SP - 83

EP - 102

BT - Principles of Immunotherapy Breast and Gastrointestinal Cancers

A2 - Ghidini, Michele

PB - Elsevier, Academic Press

ER -

Angerilli V, Andrade-Rojas JJ, Fassan M. Chapter 4 - Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers. En Ghidini M, editor, Principles of Immunotherapy Breast and Gastrointestinal Cancers. Elsevier, Academic Press. 2024. p. 83-102. (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy). doi: 10.1016/B978-0-443-13376-3.00012-5